Circulating tumor cell-derived preclinical models: current status and future perspectives by Zuzana Kahounová, Markéta Pícková, Stanislav Drápela, Jan Bouchal, Eva Szczyrbová, Jiří Navrátil, Karel Souček

Get full text

Correction: Circulating tumor cell-derived preclinical models: current status and future perspectives by Zuzana Kahounová, Markéta Pícková, Stanislav Drápela, Jan Bouchal, Eva Szczyrbová, Jiří Navrátil, Karel Souček

Get full text

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe by Stanislav Drápela, Prashant Khirsariya, Wytske M. vanWeerden, Radek Fedr, Tereza Suchánková, Diana Búzová, Jan Červený, Aleš Hampl, Martin Puhr, William R. Watson, Zoran Culig, Lumír Krejčí, Kamil Paruch, Karel Souček

Get full text

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells by Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek

Get full text